Treatment with lopinavir/ritonavir (Kaletra) reduced the risk that HIV-infected children would become co-infected with malaria, researchers said here.
Compared with treatment based on non-nucleoside reverse transcriptase inhibitors (NNRTIs), therapy with the protease inhibitor-based combination resulted in a 41% decrease in the incidence of malaria, said Jane Achan, MD, lecturer in pediatrics at Makarere University of Health Sciences, Kampala, Uganda.
The incidence rate was 2.25 malaria cases a year among those treated with NNRTIs and 1.32 cases a year with those on the protease inhibitor (P=0.04), she reported at the Conference on Retroviruses and Opportunistic Infections.
Compared with treatment based on non-nucleoside reverse transcriptase inhibitors (NNRTIs), therapy with the protease inhibitor-based combination resulted in a 41% decrease in the incidence of malaria, said Jane Achan, MD, lecturer in pediatrics at Makarere University of Health Sciences, Kampala, Uganda.
The incidence rate was 2.25 malaria cases a year among those treated with NNRTIs and 1.32 cases a year with those on the protease inhibitor (P=0.04), she reported at the Conference on Retroviruses and Opportunistic Infections.
